Skip to content
National Brain Tumor Society | Brain Tumor Investment Fund
BACK to News

[White Paper] Essential Information Isn’t Reaching Patients with Brain Tumors

Published on September 11, 2026 in White Paper, MyTumorID, Biomarker Testing, Our Impact, Clinical Trials, Educational Resources

Communication Gaps in Biomarker Testing and Clinical Trials

Executive Summary

Results from a survey of brain tumor patients and caregivers found that a lack of awareness and subsequent understanding of biomarker testing and clinical trials is linked to critical omissions during patient interactions with doctors and care teams. This deficiency in patient-provider dialogue and patient education negatively affects patients’ understanding and views of these crucial components of their diagnosis and treatment planning, and limits access to potentially beneficial treatments.

Read the full white paper

TAGGED WITH: brain cancer, brain tumor, Clinical trials, biomarker testing, MyTumorID, biomaker

Take Action this CCAM

Urge Congress to co-sponsor the BRAIN Act, strengthen funding for brain tumor research, and protect merit-based research. Act today because patients with pediatric brain tumors deserve more — more and better treatment options, more hope, and more time.

You have Successfully Subscribed!